SEC EDGARSEP 21 min read$COR

Krikorian Lazarus sold $321K of COR

Krikorian Lazarus (SVP & Chief Accounting Officer) sold 985 shares of Cencora, Inc. (COR) at $325.97 ($0.32M total) on 2026-09-01 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Krikorian Lazarus

Published Sep 2, 2026, 8:00 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 2, 2026, 8:30 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$COR

Neutral

medium confidence

Mentioned

$COR

Relevance

3/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$CORNeutralLow

Why it matters

The sale is modest and unlikely to affect market perception, but it provides transparency for investors.

Market read

Routine insider transaction with limited trading relevance.

What to watch

Potential upcoming earnings or guidance releases could change the impact of this sale.

Relevance 3/10Novelty 3/10Timing: post‑market 2026‑09‑02

Background

SEC Form 4 filing discloses an insider's open‑market sale under a 10b5‑1 plan.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CORNeutralMedium confidence

Context

SVP & Chief Accounting Officer sold 985 shares for $321,080 via a 10b5‑1 plan on 2026‑09‑01

Expected impact

minimal downward pressure, unlikely to move price materially

Evidence & confidence

The sale amount is modest relative to total holdings and market cap; insider is executing a pre‑arranged plan.

Market effects

Sector

None; the transaction is company‑specific and does not affect the broader healthcare distribution sector.

Regional

None; the filing is U.S.‑focused with no regional spillover.

Global

None; the event is limited to Cencora shareholders.

Counterpoint

What could challenge this read

If the insider sale signals concerns about upcoming challenges, a short‑term dip could be amplified.

Key entities

Officer
Krikorian Lazarus
SVP & Chief Accounting Officer of Cencora, Inc.
Company
Cencora, Inc.
U.S. pharmaceutical distribution company (ticker COR).

Read at source ← All news

SEP 10

$CORHighAI 8/10

Is Cencora Stock Underperforming the Dow?

Cencora (COR), a $61.6B pharmaceutical distributor, is down 14% from its 52-week high but up 18.5% over 3 months, outperforming the Dow. Its Q3 revenue missed estimates, but adjusted EPS beat forecasts. Analysts rate it a 'Strong Buy' with a $366.50 target, implying 12.9% upside. Peer Cardinal Health (CAH) gained 60% over the past year.

yahoo.com2 min

SEP 8

$PGNYMedAI 8/10

Q2 Earnings Outperformers: Cencora (NYSE:COR) And The Rest Of The Health Insurance Providers Stocks

Cencora (COR) is down 6.7% since reporting Q2 earnings, trading at $97.38. Progyny (PGNY) reported $350.5M revenue, up 5.3% YoY, but missed EBITDA guidance, dropping 14.1% to $25.94. Humana (HUM) reported $40.87B revenue, up 26.2% YoY, beating estimates, and rose 5% to $407.96. Cigna (CI) reported $71.56B revenue, up 6.6% YoY, beating estimates, but fell 4% to $284.64.

yahoo.com3 min

SEP 6

$CORHighAI 8/10

Why Cencora (COR) Is Getting Attention Today

Cencora (COR) reported Q3 2026 adjusted EPS of $4.48, beating estimates, and raised full-year guidance. Shares fell 1.86% to $330.95 but gained 20.75% over 90 days. The company's long-term returns are strong, with a 1-year return of 14.01% and a 5-year return of 183.23%. Analysts suggest fair value at $372.58, citing digital investments and healthcare trends.

simplywall.st2 min

AUG 23

$MCKMedAI 8/10

and Getting Worse. Here Are 2 Stocks That Turn Rising Prices Into Rising Profits.

McKesson (MCK) and Cencora (COR) are positioned to benefit from certain drug price inflation due to contractual provisions. McKesson reported $403.4B revenue and $39.11 EPS for fiscal 2026, with Q1 2027 revenue at $105.4B and EPS at $9.93. Cencora generated $321.3B revenue in fiscal 2025, with Q2 revenue at $78.4B and EPS at $4.75. Both companies have raised EPS forecasts.

aol.com3 min

AUG 21

$MCKHighAI 9/10

With Price-Increase Clauses, These Two Drug Distributors Can Withstand ‘Trumpflation’

McKesson (MCK) and Cencora (COR) benefit from drug price increases due to inflation-based compensation clauses. McKesson reported $403.4B revenue in 2026, up 12%, and raised EPS guidance. Cencora posted $321.3B revenue in 2025, up 3.8%, and increased EPS guidance. Both companies' contracts allow gains from manufacturer price hikes, but risks include regulation and cost pressures.

nai500.com3 min

AUG 20

$CVSMedAI 8/10

Health Insurance Providers Stocks Q2 Teardown: Clover Health (NASDAQ:CLOV) Vs The Rest

CVS Health (CVS) reported $106.1B revenue, up 7.3% YoY, beating estimates. Despite strong earnings, its stock fell 10.2% to $93.76. Progyny (PGNY) reported $350.5M revenue, up 5.3% YoY, but missed EBITDA guidance, causing a 15.3% stock drop to $25.58. Cencora (COR) reported $84.75B revenue, up 5.1% YoY, in line with expectations, with a 3.2% stock increase to $316.20. UnitedHealth (UNH) reported $112B revenue, flat YoY, beating estimates, but its stock fell 7.1% to $388.62.

finance.yahoo.com3 min